1/17
09:48 pm
phvs
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap [Yahoo! Finance]
Medium
Report
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap [Yahoo! Finance]
1/17
01:11 am
phvs
1/12
06:50 am
phvs
Pharvaris Outlines 2026 Strategic Priorities
Low
Report
Pharvaris Outlines 2026 Strategic Priorities
1/3
01:08 am
phvs
Medium
Report
12/21
10:19 am
phvs
What Does Wall Street Think About Pharvaris N.V. (PHVS)? [Yahoo! Finance]
Medium
Report
What Does Wall Street Think About Pharvaris N.V. (PHVS)? [Yahoo! Finance]
12/13
01:10 am
phvs
12/4
08:12 am
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/4
08:12 am
phvs
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/4
08:05 am
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.
12/3
11:37 pm
phvs
Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]
12/3
08:03 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/3
07:02 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/3
05:48 pm
phvs
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript [Seeking Alpha]
Medium
Report
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript [Seeking Alpha]
12/3
05:05 pm
phvs
Pharvaris (NASDAQ:PHVS) was given a new $38.00 price target on by analysts at Leerink Partners.
Low
Report
Pharvaris (NASDAQ:PHVS) was given a new $38.00 price target on by analysts at Leerink Partners.
12/3
02:19 pm
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
12/3
10:53 am
phvs
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment [Yahoo! Finance]
Medium
Report
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment [Yahoo! Finance]
12/3
06:50 am
phvs
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
High
Report
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
11/22
02:11 am
phvs
Low
Report
11/19
07:01 am
phvs
Pharvaris (NASDAQ:PHVS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Pharvaris (NASDAQ:PHVS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/14
12:31 pm
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
Medium
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
11/14
02:40 am
phvs
Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS) Is Up 11.3% After Deucrictibant Shows 92% Drop in HAE Attacks and Reports Q3 Loss [Yahoo! Finance]
11/13
07:45 pm
phvs
Pharvaris (PHVS): Evaluating Valuation Premium After Recent Share Price Momentum [Yahoo! Finance]
Medium
Report
Pharvaris (PHVS): Evaluating Valuation Premium After Recent Share Price Momentum [Yahoo! Finance]
11/13
09:36 am
phvs
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Wedbush from $27.00 to $30.00. They now have an "outperform" rating on the stock.
High
Report
Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Wedbush from $27.00 to $30.00. They now have an "outperform" rating on the stock.
11/13
08:11 am
phvs
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
High
Report
Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
11/12
06:50 am
phvs
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update